Search for Actavis and
  1. July 14, 2014

    Mylan in $5.3bn Abbott Laboratories deal

    US pharmaceuticals group Mylan has agreed to pay $5.3bn for the generic drugs business of Abbott Laboratories, in another...

  2. February 26, 2014

    Hedge funds should not be the only activist investors

    At 78, Carl Icahn shows little sign of retiring, or of becoming more polite. After finally prodding Forest Labs into a $25bn...

  1. February 21, 2014

    Carl Icahn, obsessive activist investor

    Steven Goldstone, when he was chief executive of RJR Nabisco, used to call the appearance of Carl Icahn “a rite of spring”....

  2. February 21, 2014

    Letter from Lex: the end of investing

    If a company that has designed a single successful mobile phone game can be worth $5bn, anything can be worth anything, and...

  3. February 19, 2014

    Eli Lilly jumps after cancer drug trial

    Shares in Eli Lilly climbed after the US pharmaceuticals group said a study of a lung cancer treatment increased survival...

  4. FT Alphaville

    February 18, 2014

    The Closer

    FURTHER FURTHER READING - Kevin Roose crashes a Wall Street secret society. - Minimum wage by the numbers. - Arnold Kling...

  5. February 18, 2014

    Actavis chief Bisaro finds prescription for growth

    Paul Bisaro, the outspoken chief executive of drugs company Actavis, has quickly gained a reputation as an ambitious...

  6. February 18, 2014

    Actavis / Forest: roll up, tax down

    Buy drug company, cut operating costs, cut research spending, pay less tax, watch stock go up. It is a simple plan, and...

  7. February 18, 2014

    Actavis buys Forest Laboratories for $25bn

    Actavis, the highly acquisitive Dublin-based drugs maker, has agreed to buy New York’s Forest Laboratories for $25bn, its...

  8. August 25, 2013

    Amgen’s $10.5bn takeover of Onyx approved by both boards

    Amgen said on Sunday night that its takeover of Onyx, the US cancer drug developer, at $125 a share had been approved by...

  9. July 29, 2013

    Perrigo / Elan: tax shopping

    Remember the quaint old days, when mergers aimed for cost savings? Ah, the deals of yesteryear. It is all about taxes now....

  10. June 19, 2013

    Lundbeck fined €94m for ‘pay for delay’ deals to rivals

    European regulators have fined Lundbeck, the Danish pharmaceutical company, €94m for paying rivals to delay cut-price...

  11. June 17, 2013

    Payments to delay generic drug rivals to be scrutinised

    Payments by drug companies to delay generic competition will be open to fresh antitrust scrutiny in the US, following a...

  12. May 28, 2013

    Generic drugs: Watchdogs probe pay-for-delay deals

    Sir Andrew Witty winces at the term, but the chief executive of GlaxoSmithKline is one of a growing number of chief...

  13. May 24, 2013

    Valeant nears $9bn Bausch & Lomb deal

    Valeant is closing in on a deal to acquire Bausch & Lomb for about $9bn, said people familiar with the matter. The deal came...

  14. May 20, 2013

    Actavis / Warner Chilcott: simple medicine

    Hopefully it is as sensible as it looks. Warner Chilcott has agreed to be bought by Actavis for $8.5bn. The deal lacks flash...

  15. May 20, 2013

    Dealmaking fails to send Wall St higher

    US stocks saw muted losses that sent the S&P retreating from record levels, despite a burst of dealmaking to start the week....

  16. May 20, 2013

    Actavis to acquire Warner Chilcott in $5bn pharmaceutical deal

    Actavis sought to fend off takeover threats by purchasing Dublin-based rival Warner Chilcott in a $5bn deal designed to turn...

  17. May 10, 2013

    Actavis in talks to buy Warner Chilcott

    Actavis, the generic drugmaker, is in early discussions to buy Warner Chilcott, a pharmaceuticals company valued at more...

  18. April 27, 2013

    Valeant and Actavis held $35bn merger talks

    Valeant Pharmaceuticals International and generic drugmaker Actavis were recently working on a merger that would have...

  19. April 2, 2013

    AstraZeneca loses US drug patent judgment

    AstraZeneca’s portfolio of patent-protected drugs has been trimmed back after the pharmaceuticals group lost a legal...

  20. June 25, 2012

    Shire shares slump as rival drug approved

    More than £1bn was wiped from Shire’s market capitalisation on Monday after the US Food and Drug Administration widened the...

  21. June 25, 2012

    Ephemeral fortresses

    Angus Russell, chief executive of Shire, is a sand castle builder, like all drug company bosses. The rising tide of generic...

  22. June 18, 2012

    Drug groups warn over new EU law

    European patients face the prospect of medicine shortages if legislation designed to ensure the high quality of ingredients...

  23. May 6, 2012

    Generic rivals are also being blown off-course

    The strong headwinds facing big pharmaceutical groups are due in part to pressure from the rise of generic rivals. But many...

  24. May 6, 2012

    HgCapital puts up Mercury Pharma for sale

    Mercury Pharma, the generic drugs group previously known as Goldshield, has been put up for sale by its private equity owner...

  25. May 3, 2012

    Sandoz gains dermatology lead with Fougera

    Novartis’s generic drugs division Sandoz has agreed to buy Fougera Pharmaceuticals for $1.53bn in cash in a deal that...

  26. April 26, 2012

    Watson expects earnings boost from deal

    Watson expects to boost earnings following completion of its €4.5bn agreed takeover of Actavis, which has created one of the...

  27. April 24, 2012

    Watson set to buy Actavis for €4.5bn

    Deutsche Bank is close to clearing its books of the largest loan it has been saddled with as a legacy of the credit crisis,...

  28. FT Alphaville

    March 21, 2012

    The Closer

    Round-up US equities sagged, a bit. The S&P 500 fell 0.2 per cent and the DJIA dropped 0.3 per cent, its second down day...

  29. March 21, 2012

    Watson in talks to acquire Actavis

    Watson Pharmaceuticals, the US generic drugmaker, is in talks to acquire Actavis in a deal that could value it Swiss rival...

  30. March 21, 2012

    US stocks edge down

    US equities fell for a second straight day as new housing data showed that existing home sales slipped in February, even as...

  31. January 22, 2012

    Pharma groups brace for costly settlements

    Medical companies are braced for a series of costly settlements this year over actions brought by US agencies for alleged...

  32. October 27, 2011

    AstraZeneca indicted in Serbian corruption case

    AstraZeneca has been served with a criminal indictment by the Serbian authorities as part of a widening probe into alleged...

  33. March 22, 2010

    The Real Deal

    Deutsche Bank has had a thumping headache for months. But Pfizer may be able to cure it.Back in 2007 the German bank...

  34. March 21, 2010

    Pfizer could ease Deutsche Bank’s pain

    Deutsche Bank has had a thumping headache for months. But Pfizer may be able to cure it. Back in 2007 the German bank...

  35. March 19, 2010

    Teva to buy Ratiopharm for €3.6bn

    The German Merckle family has agreed to sell generic drugmaker Ratiopharm to Israel's Teva in a €3.6bn ($4.9bn) deal that...

  36. March 18, 2010

    Teva secures €3.5bn Ratiopharm deal

    The German Merckle family has agreed to sell generic drugmaker Ratiopharm to Israel’s Teva in a €3.6bn ($4.9bn) deal that...

  37. March 7, 2010

    Linpac faces sale as lenders flip assets

    Lenders to Linpac are planning to break up and sell Europe’s biggest food packaging group in a sign that banks are seeking...

  38. FT Alphaville

    March 3, 2010

    Pfizer pursues Ratiopharm

    Pfizer, the world’s biggest drugmaker, is bidding as much as €3bn ($4.08bn) for German generic-drug maker Ratiopharm and...

Search for Actavis and